COLLPLANT BIOTECH. IS-01 (CPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has a cash flow conversion efficiency ratio of -0.483x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.94 Million ≈ $-3.43 Million USD) by net assets (€6.08 Million ≈ $7.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COLLPLANT BIOTECH. IS-01 (CPT) market capitalisation for the company's overall valuation and market capitalisation.
COLLPLANT BIOTECH. IS-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's cash flow conversion efficiency has evolved over time, based on yearly financial data.
COLLPLANT BIOTECH. IS-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their cash flow conversion efficiency. Explore how high is COLLPLANT BIOTECH. IS-01's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsodilo Resources Limited
V:TSD
|
-0.026x |
|
Cascadero Copper Corp
V:CCD
|
0.082x |
|
BIRKS GROUP INC. A
F:2BG
|
N/A |
|
Gratomic Inc
V:GRAT
|
-0.003x |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-1.130x |
|
Binani Industries Limited
NSE:BINANIIND
|
0.019x |
|
Kedaung Indah Can Tbk
JK:KICI
|
-0.009x |
|
K9 Gold Corp
V:KNC
|
-0.612x |
Annual Cash Flow Conversion Efficiency for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. View latest COLLPLANT BIOTECH. IS-01 stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
€-9.42 Million ≈ $-11.01 Million |
-1.549x | -47.99% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
€-14.09 Million ≈ $-16.48 Million |
-1.047x | -973.53% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
€-2.76 Million ≈ $-3.23 Million |
-0.097x | +77.02% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
€-13.70 Million ≈ $-16.01 Million |
-0.424x | -865.55% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
€2.50 Million ≈ $2.92 Million |
0.055x | -- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more